Recombinant MSCs (mesenchymal stem cells) as well as preparation method and application thereof in preparation of drug for treating ALF (acute liver failure)

Abstract

The invention discloses a recombinant MSCs (mesenchymal stem cells) as well as a preparation method and an application thereof in preparation of a drug for treating ALF (acute liver failure). The recombinant MSCs are obtained by infecting MSCs with recombinant lentivirus, wherein the recombinant lentivirus is obtained after recombinant plasmid over-expressing PTGS2 and a lentivirus packaging vector transfect cells; and the recombinant plasmid over-expressing PTGS2 is prepared from a former primer sequence and a rear primer sequence for amplifying PTGS2 and an empty plasmid vector Ubi-MCS-3FLAG-CBh-gcGFP-IRES-puromycin. The treatment effect of MSCs on the ALF can be improved.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to the application of a medicine for treating acute liver failure, in particular to a recombinant mesenchymal stem cell and its preparation method and its application in the preparation of medicine for treating acute liver failure. Background technique [0002] Acute liver failure (ALF) is a severe clinical disease characterized by rapid and massive necrosis of liver cells and a sharp decline in liver function. At present, liver transplantation is the most effective method for the treatment of ALF, but its application is limited due to the shortage of donor liver sources. Stem cell transplantation has been considered an effective way to treat a variety of liver diseases, and mesenchymal stem cells (MSCs) are just one of them, which have been proven to alleviate a variety of acute or chronic liver diseases. However, the results of clinical trials show that the therapeutic effect is not satis...

AI Technical Summary

Problems solved by technology

[0005] At present, the application of MSCs transplantation to treat ALF is a promising treatment approach, but there are still some defects: 1. The main pathological change of ALF is that a large number of liver cells die beyond the compensatory ability of the liver itself, and various factors (drugs, viruses, etc.) ) induces massive necrosis of liver cells, releases a large number of damage-associated molecular patterns (damage-associated molecular patterns, DAMPs), which are recognized by the innate immune system in the liver, such as monocytes, macrophages and dendritic cells, etc., and then produce a large number of Inflammatory factors can further cause liver damage and loss of liver function. Therefore, in order to ensure timely and effective clinical treatment of ALF, allogeneic MSCs are a better choice; 2. So far, many studies at home and abroad have also found that stem cell transplantation is not effective. Good phenomenon

A retrospective study of this series of literature found that there are two main reasons that restrict the efficacy of MSC transplantation. One is the low colonization efficiency of transplanted MSCs in the liver, and the other is the excessive inflammatory response in liver failure. It has a certain damage effect on the transplanted MSC

Images